查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1918449

基於人工智慧的胜肽類藥物發現平台市場（按技術類型、治療用途、胜肽和最終用戶分類）—2026-2032年全球預測

AI-driven Peptide Drug Discovery Platform Market by Technology Type, Therapeutic Application, Peptide Class, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

人工智慧驅動的胜肽藥物發現平台市場預計到 2025 年將達到 10.8 億美元，到 2026 年將成長到 12.1 億美元，到 2032 年將達到 24.4 億美元，複合年成長率為 12.29%。

關鍵市場統計數據
基準年 2025 10.8億美元
預計年份：2026年 12.1億美元
預測年份 2032 24.4億美元
複合年成長率 (%) 12.29%

策略實施：運算能力與胜肽化學的融合正在重塑藥物發現的優先事項，並加速生物製藥領域的轉化決策。

人工智慧驅動的胜肽類藥物發現平台的出現，標誌著計算創新與胜肽化學的融合，重塑了治療藥物研發的早期階段。過去幾年，演算法建模的進步、計算能力的提升以及生物資料集的日益豐富，加速了具有更高特異性、穩定性和可生產性的胜肽類候選藥物的篩選。本文闡述了將以資料為中心的藥物發現流程整合到企業研發體系中的策略價值，重點介紹了機器輔助設計如何縮短候選藥物篩選時間，同時為後續研發環節提供更可靠的決策支援。

快速的演算法進步、豐富的生物數據和可擴展的計算基礎設施如何改變胜肽類藥物發現工作流程和實用化預期

胜肽類藥物發現領域正經歷著一場變革，這場變革由三個相互關聯的因素所驅動：演算法的複雜性、數據的可用性和操作的擴充性。深度學習架構正在不斷發展，以更高的精度模擬序列-結構-功能關係，而基於圖的方法和循環模型則能夠對胜肽的相互作用和結構動態進行細緻入微的表徵。同時，高品質基因組學和蛋白​​質組學資料集的激增以及更豐富的檢測結果的出現，正在增強模型的訓練和檢驗，使得計算假設能夠更可靠地轉化為實驗檢驗。

評估2025年美國關稅對胜肽類藥物研發供應鏈、計算策略和實驗優先排序的多面向影響

2025年美國關稅的累積影響將為胜肽類藥物研發價值鏈上的企業帶來複雜的挑戰與策略轉捩點。影響實驗室試劑、專用胜肽合成耗材以及某些計算硬體組件的關稅將增加實驗流程和基礎設施投資的落地成本，進而影響籌資策略和計劃優先排序。為此，一些企業正在考慮將關鍵合成產能遷回國內，或加強與區域供應商的合作，以確保供應的連續性和價格的可預測性。然而，這些供應側措施通常需要前期投資和營運重組。

從技術架構、治療領域重點、最終用戶需求、胜肽類藥物模式和工作流程步驟等方面進行全面的觀點，從而實現策略平台選擇和優先排序。

細緻的細分分析揭示了技術選擇、治療領域、最終用戶畫像、胜肽和工作流程階段如何相互作用，從而定義獨特的價值池和能力需求。從技術角度來看，平台涵蓋範圍廣泛，從基於雲端的選項（包括混合雲端、私有雲端和公共雲端部署）、深度學習方法（例如卷積類神經網路、圖神經網路和循環神經網路）、傳統機器學習範式（例如強化學習、監督學習和無監督學習），到利用傳統高效能運算和專用伺服器的本地部署平台。每種技術路徑在可擴展性、資料管治以及演算法對序列最佳化和結構預測等任務的適用性方面都存在權衡取捨。

美洲、歐洲、中東和非洲以及亞太地區的趨勢正在影響胜肽類藥物研發舉措的平台採用、監管策略和供應鏈在地化。

區域趨勢將顯著影響從事人工智慧驅動胜肽類藥物研發機構的投資決策、監管應對措施和供應鏈設計。在美洲，強大的創新生態系統、完善的創業融資管道以及位置的生物技術和製藥公司，促進了計算平台的快速應用以及產業界與學術實驗室之間的緊密合作。許多地區的監管政策清晰明確，支付體系完善，鼓勵開展能夠展現明確臨床價值和可重複性的轉化研究項目，而國內的生產能力則為早期候選藥物的臨床供應提供了保障。

結合胜肽化學專業知識和先進人工智慧技術以加速轉化研發流程的公司之間，存在著一些關鍵的競爭和合作趨勢。

主要企業層面的洞察揭示了通用人工智慧應用於胜肽類藥物發現的領先企業所共有的策略模式。成功的公司通常會將胜肽化學專業知識與先進的運算能力結合，從而建立反饋迴路，加速模型最佳化和實驗檢驗。他們投資跨職能團隊，連接資料科學、結構生物學、藥物化學和轉化科學，以確保In Silico預測能夠迅速透過經驗數據得到驗證，並不斷迭代改進。

產業領導者應立即採取高影響力行動，協調平台選擇、管治和夥伴關係，以加速、降低風險地開發胜肽類藥物。

產業領導者應採取一套重點突出、切實可行的策略，將分析優勢轉化為持續的治療和商業性成果。首先，應根據組織的風險狀況選擇合適的平台，評估雲端擴展、混合部署或本地部署哪種方案最能滿足資料隱私、監管限制和整體成本目標。其次，應優先組成整合團隊，將計算模型開發人員、實驗室研究人員和臨床醫生聚集在一起，以確保快速回饋和持續的模型檢驗。此外，還應建立迭代循環機制，並利用實驗結果重新訓練和改進演算法。

我們採用嚴謹的混合方法研究方法，結合一手訪談、技術審查和多源三角驗證，以檢驗平台的說法和策略意義。

本研究整合了一手和二手研究方法，旨在提供基於實證的人工智慧賦能肽類藥物發現現狀分析。一手研究包括對製藥和生物技術公司、受託研究機構（CRO）、學術實驗室和技術提供者的領導層進行結構化訪談，並輔以對平台架構和檢驗研究的技術審查。二手研究則利用同行評審文獻、監管指導文件、臨床試驗註冊資訊和公開資訊，為研發路徑和治療重點提供背景資料。這些資訊經過三角驗證，以確保結論的穩健性，並突顯各相關人員之間的共識和分歧。

總之，我們總結了將人工智慧平台與營運嚴謹性和策略夥伴關係相結合的見解，以將計算胜肽藥物發現轉化為臨床上有用的治療方法。

總之，人工智慧驅動的胜肽類藥物發現正從實驗創新階段過渡到企業加速治療產品線研發的營運基礎階段。深度學習和基於圖的建模技術的進步，結合可擴展的計算資源和豐富的生物資料集，使得In Silico模擬假設的生成和優先排序更加可靠。當這些能力得到確保可重複性和監管可追溯性的管治實踐的支持，並融入跨職能團隊時，才能發揮最大效用。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：基於人工智慧的胜肽類藥物發現平台市場（按技術類型分類）

  • 基於雲端的平台
    • 混合雲端
    • 私有雲端
    • 公共雲端
  • 深度學習平台
    • 卷積類神經網路
    • 圖神經網路
    • 循環神經網路
  • 機器學習平台
    • 強化學習
    • 監督式學習
    • 無監督學習
  • 本地部署平台
    • 傳統高效能運算
    • 專用伺服器

9. 以人工智慧為基礎的胜肽類藥物發現平台市場（依治療領域分類）

  • 心血管系統
    • 動脈粥狀硬化
    • 心臟衰竭
  • 感染疾病
    • 細菌
    • 病毒性疾病
  • 代謝性疾病
    • 糖尿病
    • 肥胖
  • 神經系統疾病
    • 阿茲海默症
    • 帕金森氏症
  • 腫瘤學
    • 骨髓惡性腫瘤
    • 固態腫瘤

第10章：基於人工智慧的胜肽藥物發現平台市場（按胜肽分類）

  • 環肽
    • 從頭到尾
    • 側鏈鍵類型
  • 線性胜肽
    • 長鏈胜肽
    • 短胜肽
  • 胜肽類似物
    • BETA胜肽
    • 胜肽類

第11章：基於人工智慧的胜肽藥物發現平台市場（按最終用戶分類）

  • 學術和政府研究機構
    • 私人研究機構
    • 公共研究機構
  • 合約研究機構
    • 大型CRO機構
    • 小規模CRO組織
  • 製藥和生物技術公司
    • 生技公司
    • 製藥公司

第12章：基於人工智慧的胜肽類藥物發現平台市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：基於人工智慧的胜肽類藥物發現平台市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國基於人工智慧的胜肽類藥物發現平台市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國基於人工智慧的胜肽類藥物發現平台市場

第16章：中國基於人工智慧的胜肽類藥物發現平台市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Atombeat, Inc.
  • Aurigene Discovery Technologies Limited
  • Cradle, Inc.
  • Creative Peptides, Inc.
  • Deep Genomics Inc.
  • DenovAI Biotech, Inc.
  • Fujitsu Limited
  • Generate Biomedicines, Inc.
  • Gubra ApS
  • Iktos SA
  • Insilico Medicine, Inc.
  • Koliber Biosciences, Inc.
  • Numerion Labs, Inc.
  • Nuritas Limited
  • Pepticom, Inc.
  • Peptilogics, Inc.
  • Relay Therapeutics, Inc.
  • Space Peptides, Inc.
Product Code: MRR-AE420CB1555D

The AI-driven Peptide Drug Discovery Platform Market was valued at USD 1.08 billion in 2025 and is projected to grow to USD 1.21 billion in 2026, with a CAGR of 12.29%, reaching USD 2.44 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.08 billion
Estimated Year [2026] USD 1.21 billion
Forecast Year [2032] USD 2.44 billion
CAGR (%) 12.29%

A strategic introduction to how combined computational power and peptide chemistry are reshaping discovery priorities and accelerating translational decision-making in biopharma

The emergence of AI-driven platforms for peptide drug discovery represents a convergence of computational innovation and peptide chemistry that is reshaping early-stage therapeutic development. Over the past several years, advances in algorithmic modeling, increased computational power, and richer biological datasets have accelerated the identification of peptide candidates with improved specificity, stability, and manufacturability. This introduction frames the strategic value of integrating data-centric discovery pipelines into organizational R&D, emphasizing how machine-assisted design reduces time to candidate selection while enabling higher-confidence decisions upstream in the pipeline.

Today's platform architectures vary from cloud-native solutions that scale training workloads to on-premise deployments designed to protect sensitive datasets, and this diversity reflects differing institutional risk tolerances and regulatory constraints. In parallel, the therapeutic landscape for peptides stretches across cardiovascular, infectious disease, metabolic, neurological, and oncology indications, each presenting unique target classes and validation needs. Academia and government laboratories continue to generate mechanistic insights, contract research organizations operationalize validation workflows, and pharmaceutical and biotechnology firms focus on translation and commercialization. By situating AI-driven peptide discovery within this ecosystem, stakeholders can better prioritize investments in platform capabilities, data governance, and cross-functional workflows that bridge computational predictions with empirical validation.

In short, integrating AI into peptide discovery is not a one-off efficiency gain but a structural shift that demands coordinated changes across technology selection, talent, and experimental pipelines to realize sustained competitive advantage.

How rapid algorithmic advances, richer biological data, and scalable compute infrastructures are jointly transforming peptide discovery workflows and translational expectations

The landscape of peptide drug discovery is undergoing transformative shifts driven by three intertwined forces: algorithmic sophistication, data availability, and operational scalability. Deep learning architectures have evolved to model sequence-structure-function relationships with increasing fidelity, while graph-based methods and recurrent models enable nuanced representations of peptide interactions and conformational dynamics. Concurrently, the proliferation of high-quality genomics and proteomics datasets, along with richer assay readouts, has enhanced model training and validation, enabling computational hypotheses to be more reliably translated into experimental testing.

Operationally, cloud and hybrid deployment models now allow organizations to scale compute-intensive tasks such as molecular dynamics and generative modeling without prohibitive capital expenditure, while on-premise high-performance computing remains critical for institutions with strict data governance requirements. These technological shifts have catalyzed new collaborative structures: cross-disciplinary teams that couple computational scientists, medicinal chemists, and translational biologists are becoming standard operating practice rather than experimental exceptions. As a result, discovery timelines are compressing and the barrier to iterative design cycles is falling.

Moreover, regulatory and reimbursement environments are starting to recognize the role of in silico evidence in de-risking early development, and payers are paying attention to modality-specific value propositions. Together, these transformative shifts are not only altering how candidates are discovered but also redefining expectations for speed, reproducibility, and transparency in preclinical decision-making.

Evaluating the multifaceted effects of 2025 United States tariffs on peptide discovery supply chains, compute strategies, and experimental prioritization

The cumulative impact of United States tariffs in 2025 introduces complex headwinds and strategic inflection points for organizations operating across the peptide discovery value chain. Tariffs affecting laboratory reagents, specialized peptide synthesis inputs, and select computational hardware components can increase the landed cost of experimental workflows and infrastructure investments, thereby influencing procurement strategies and project prioritization. In response, some organizations are exploring reshoring of critical synthesis capabilities or forming closer partnerships with regional suppliers to stabilize supply continuity and pricing predictability. These supply-side mitigations, however, often require upfront capital commitments and operational retooling.

On the computational front, tariffs that raise the cost of server-class GPUs and related accelerators will likely accelerate interest in cloud-based consumption models where total cost of ownership can be shifted from capital expenditure to operating expenditure. Conversely, entities with stringent data residency or IP protection needs may double down on localized hardware investments, accepting higher costs to preserve control. Tariffs also precipitate indirect effects: increased import costs for lab consumables may concentrate experimentation on in silico approaches and high-throughput virtual screening to reduce wet-lab iterations, thereby favoring platforms that deliver robust predictive accuracy and integration with automation.

Ultimately, the 2025 tariff landscape is reshaping both sourcing strategies and the relative value of computational versus experimental investments. Organizations that proactively redesign procurement, diversify supplier footprints across regions, and optimize hybrid compute architectures will be better positioned to manage cost pressures while sustaining innovation velocity.

A comprehensive segmentation perspective linking technology architectures, therapeutic focuses, end-user needs, peptide modalities, and workflow stages to strategic platform selection and prioritization

A nuanced segmentation analysis reveals how technology choices, therapeutic focus, end-user profiles, peptide classes, and workflow stages collectively define distinct value pools and capability requirements. From a technology perspective, platforms span cloud-based options-encompassing hybrid cloud, private cloud, and public cloud deployments-deep learning approaches that include convolutional neural networks, graph neural networks, and recurrent neural networks, traditional machine learning paradigms such as reinforcement learning, supervised learning, and unsupervised learning, and on-premise platforms that leverage conventional high-performance computing and dedicated servers. Each technology path carries trade-offs in scalability, data governance, and algorithmic suitability for tasks like sequence optimization or structural prediction.

Therapeutic application segmentation includes cardiovascular projects targeting atherosclerosis and heart failure, infectious disease efforts addressing bacterial and viral targets, metabolic disorder programs focused on diabetes and obesity, neurological pursuits in Alzheimer's and Parkinson's, and oncology workstreams spanning hematological malignancies and solid tumors. These indications vary in target tractability, biomarker availability, and clinical validation pathways, which in turn influence the optimal balance between in silico screening and empirical validation.

End users comprise academic and government research institutes-further differentiated into private and public research entities-contract research organizations divided between large and small CROs, and pharmaceutical and biotechnology companies segmented into biotechnology firms and established pharmaceutical companies. Distinctions across these groups affect procurement cycles, risk tolerances, and internal versus outsourced validation strategies. Regarding peptide class, cyclic peptides with head-to-tail or side chain-to-side chain cyclizations, linear peptides categorized as long or short, and peptidomimetics such as beta peptides and peptoids each present unique design challenges and manufacturing considerations. Finally, workflow-stage segmentation covers target identification via genomics and proteomics, lead generation through high-throughput and in silico screening, preclinical validation in vitro and in vivo, and clinical development across Phase I, Phase II, and Phase III. Understanding how these segments interrelate enables organizations to align platform capabilities with therapeutic objectives and operational constraints more precisely.

How Americas, Europe Middle East & Africa, and Asia-Pacific regional dynamics shape platform adoption, regulatory strategy, and supply chain localization for peptide discovery initiatives

Regional dynamics materially influence investment decisions, regulatory navigation, and supply chain design for organizations engaged in AI-driven peptide discovery. In the Americas, a robust innovation ecosystem, well-established venture funding channels, and a dense concentration of biotechnology and pharmaceutical companies foster rapid adoption of computational platforms and close integration between industry and academic labs. Regulatory clarity and sophisticated payer systems in many jurisdictions incentivize translational programs that demonstrate clear clinical value and reproducibility, while domestic manufacturing capacity supports clinical supply for early-stage candidates.

Across Europe, the Middle East & Africa, regulatory fragmentation and diverse reimbursement frameworks necessitate adaptive strategies that emphasize interoperability, data protection compliance, and localized partnerships. Europe's strong academic networks and specialized contract research organizations provide deep domain expertise, but cross-border data transfer rules and regional procurement policies can complicate centralized platform deployment. Investment in hybrid cloud architectures and regional data centers helps mitigate these constraints.

In the Asia-Pacific region, a combination of rapid manufacturing expansion, growing clinical trial capacity, and large patient populations offers significant opportunities for accelerated development and regional commercialization. Governments in several countries are actively supporting biotech innovation through incentives and funding, which can lower barriers to scaling peptide manufacturing and clinical studies. However, heterogeneity in regulatory standards and IP enforcement requires careful market-entry planning and often favors strategic collaborations with local partners to expedite regulatory approvals and supply chain localization. Taking a regionally informed approach to platform deployment, supplier selection, and partnership models is essential to unlocking value across these diverse markets.

Critical competitive and partnership dynamics observed among firms combining peptide chemistry expertise with advanced AI capabilities to accelerate translational pipelines

Key company-level insights reveal recurring strategic patterns among organizations that are leading the integration of AI into peptide drug discovery. Successful companies typically combine domain expertise in peptide chemistry with advanced computational capabilities, creating feedback loops that accelerate model refinement and experimental validation. They invest in cross-functional teams that bridge data science, structural biology, medicinal chemistry, and translational science, ensuring that in silico predictions are rapidly assessed and iteratively improved using empirical data.

Partnership models also stand out: collaborations between platform developers and contract research organizations or academic laboratories enable access to specialized assays and patient-derived datasets, while strategic alliances with manufacturing partners secure scalability for promising candidates. From a product strategy perspective, firms that offer modular platforms-enabling customers to adopt cloud, hybrid, or on-premise configurations-tend to capture a broader set of enterprise clients because they address varied data governance and cost preferences.

Operationally, investment in robust validation frameworks and transparent model explainability increases buyer confidence, particularly when platforms are used to prioritize or de-risk preclinical programs. Firms that couple technical roadmaps with clear regulatory engagement strategies and evidence-generation plans position themselves favorably for enterprise adoption. Finally, organizations that maintain flexible commercial models, including licensing, outcome-linked arrangements, and collaborative research agreements, demonstrate greater resilience in addressing diverse customer procurement cycles and risk appetites.

High-impact actions industry leaders can implement now to align platform choices, governance, and partnerships for rapid and de-risked peptide therapeutic development

Industry leaders should adopt a set of focused, actionable strategies to translate analytic advantages into sustained therapeutic and commercial outcomes. First, align platform selection with organizational risk posture by evaluating whether cloud scaling, hybrid deployments, or on-premise investments best match data sensitivity, regulatory constraints, and total cost objectives. Next, prioritize the formation of integrated teams that pair computational modelers with bench scientists and clinicians to ensure rapid feedback and continuous model validation; institutionalize iterative cycles where experimental results are used to retrain and refine algorithms.

Additionally, diversify supply chains and consider regional manufacturing or supplier partnerships to mitigate tariff and logistical risks, while preserving flexibility through hybrid compute strategies that leverage cloud bursting for peak workloads. Invest in model transparency and standardized validation protocols to build credibility with regulators and collaborators; provide reproducible evidence packages that demonstrate predictive performance across relevant peptide classes and therapeutic contexts. Pursue strategic alliances that grant access to high-quality datasets and specialized assays, and design commercial terms that balance upfront fees with milestone or outcome-based payments to align incentives with customers.

Finally, cultivate a governance framework for data stewardship that addresses privacy, provenance, and reuse. By implementing these measures, organizations can reduce translational friction, accelerate candidate progression, and position themselves to capture downstream value as peptide therapeutics mature toward clinical and commercial milestones.

A rigorous mixed-methods research approach combining primary interviews, technical review, and multi-source triangulation to validate platform claims and strategic implications

This research synthesizes primary and secondary methods to produce an evidence-driven view of the AI-driven peptide discovery landscape. Primary research included structured interviews with leaders across pharmaceutical and biotechnology companies, contract research organizations, academic laboratories, and technology providers, complemented by technical reviews of platform architectures and validation studies. Secondary research drew on peer-reviewed literature, regulatory guidance documents, clinical trial registries, and public disclosures to contextualize development pathways and therapeutic priorities. These inputs were triangulated to ensure robustness and to surface areas of consensus and divergence across stakeholders.

Analytical techniques included qualitative thematic analysis to identify common challenges and strategic responses, as well as comparative assessments of technology approaches across workflow stages. Validation steps involved cross-referencing interview insights with documented case examples and assessing model performance claims against available benchmarking studies. Regional and tariff-related analyses incorporated trade policy documentation and supply chain mapping to evaluate potential operational impacts. Throughout, the methodology emphasized transparency in assumptions, reproducibility in data synthesis, and the use of multiple evidence streams to mitigate single-source bias.

The result is a structured framework that links technological capabilities to therapeutic application needs and operational constraints, supporting practical recommendations for platform selection, partnership models, and implementation sequencing.

Concluding insights on integrating AI platforms with operational rigor and strategic partnerships to translate computational peptide discovery into clinically relevant therapeutics

In conclusion, AI-driven peptide discovery is transitioning from experimental innovation to an operational cornerstone for organizations intent on accelerating therapeutic pipelines. Technological advances in deep learning and graph-based modeling, paired with scalable compute options and richer biological datasets, are enabling more reliable in silico hypothesis generation and prioritization. These capabilities are most effective when embedded within cross-functional teams and supported by governance practices that ensure reproducibility and regulatory traceability.

The 2025 tariff environment and regional heterogeneity in regulation and manufacturing capacity introduce pragmatic constraints that require adaptive procurement and partnership strategies. By aligning technology choices-whether cloud, hybrid, or on-premise-with data governance requirements, and by investing in supplier diversification and regional partnerships, organizations can maintain innovation velocity while managing cost and compliance risks. Firms that combine technical rigor with clear validation evidence, flexible commercial terms, and strategic collaborations will be best positioned to convert computational predictions into clinically meaningful peptide therapeutics.

Ultimately, success will favor organizations that treat AI platforms not as isolated tools but as integral elements of an end-to-end discovery-to-clinic strategy, continuously integrating empirical learning and market feedback to refine both models and operational approaches.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. AI-driven Peptide Drug Discovery Platform Market, by Technology Type

  • 8.1. Cloud Based Platform
    • 8.1.1. Hybrid Cloud
    • 8.1.2. Private Cloud
    • 8.1.3. Public Cloud
  • 8.2. Deep Learning Platform
    • 8.2.1. Convolutional Neural Network
    • 8.2.2. Graph Neural Network
    • 8.2.3. Recurrent Neural Network
  • 8.3. Machine Learning Platform
    • 8.3.1. Reinforcement Learning
    • 8.3.2. Supervised Learning
    • 8.3.3. Unsupervised Learning
  • 8.4. On Premise Platform
    • 8.4.1. Conventional Hpc
    • 8.4.2. Dedicated Servers

9. AI-driven Peptide Drug Discovery Platform Market, by Therapeutic Application

  • 9.1. Cardiovascular
    • 9.1.1. Atherosclerosis
    • 9.1.2. Heart Failure
  • 9.2. Infectious Diseases
    • 9.2.1. Bacterial
    • 9.2.2. Viral
  • 9.3. Metabolic Disorders
    • 9.3.1. Diabetes
    • 9.3.2. Obesity
  • 9.4. Neurological
    • 9.4.1. Alzheimers
    • 9.4.2. Parkinsons
  • 9.5. Oncology
    • 9.5.1. Hematological Malignancies
    • 9.5.2. Solid Tumors

10. AI-driven Peptide Drug Discovery Platform Market, by Peptide Class

  • 10.1. Cyclic Peptides
    • 10.1.1. Head To Tail
    • 10.1.2. Side Chain To Side Chain
  • 10.2. Linear Peptides
    • 10.2.1. Long Peptides
    • 10.2.2. Short Peptides
  • 10.3. Peptidomimetics
    • 10.3.1. Beta Peptides
    • 10.3.2. Peptoids

11. AI-driven Peptide Drug Discovery Platform Market, by End User

  • 11.1. Academic & Government Research Institutes
    • 11.1.1. Private Research Institutes
    • 11.1.2. Public Research Institutes
  • 11.2. Contract Research Organizations
    • 11.2.1. Large Cro Organizations
    • 11.2.2. Small Cro Organizations
  • 11.3. Pharmaceutical & Biotechnology Companies
    • 11.3.1. Biotechnology Companies
    • 11.3.2. Pharmaceutical Companies

12. AI-driven Peptide Drug Discovery Platform Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. AI-driven Peptide Drug Discovery Platform Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. AI-driven Peptide Drug Discovery Platform Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States AI-driven Peptide Drug Discovery Platform Market

16. China AI-driven Peptide Drug Discovery Platform Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Atombeat, Inc.
  • 17.6. Aurigene Discovery Technologies Limited
  • 17.7. Cradle, Inc.
  • 17.8. Creative Peptides, Inc.
  • 17.9. Deep Genomics Inc.
  • 17.10. DenovAI Biotech, Inc.
  • 17.11. Fujitsu Limited
  • 17.12. Generate Biomedicines, Inc.
  • 17.13. Gubra ApS
  • 17.14. Iktos SA
  • 17.15. Insilico Medicine, Inc.
  • 17.16. Koliber Biosciences, Inc.
  • 17.17. Numerion Labs, Inc.
  • 17.18. Nuritas Limited
  • 17.19. Pepticom, Inc.
  • 17.20. Peptilogics, Inc.
  • 17.21. Relay Therapeutics, Inc.
  • 17.22. Space Peptides, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY TECHNOLOGY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PEPTIDE CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CLOUD BASED PLATFORM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CLOUD BASED PLATFORM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CLOUD BASED PLATFORM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CLOUD BASED PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY HYBRID CLOUD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY HYBRID CLOUD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY HYBRID CLOUD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PRIVATE CLOUD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PRIVATE CLOUD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PRIVATE CLOUD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PUBLIC CLOUD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PUBLIC CLOUD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PUBLIC CLOUD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY DEEP LEARNING PLATFORM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY DEEP LEARNING PLATFORM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY DEEP LEARNING PLATFORM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY DEEP LEARNING PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CONVOLUTIONAL NEURAL NETWORK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CONVOLUTIONAL NEURAL NETWORK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CONVOLUTIONAL NEURAL NETWORK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY GRAPH NEURAL NETWORK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY GRAPH NEURAL NETWORK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY GRAPH NEURAL NETWORK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY RECURRENT NEURAL NETWORK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY RECURRENT NEURAL NETWORK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY RECURRENT NEURAL NETWORK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY MACHINE LEARNING PLATFORM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY MACHINE LEARNING PLATFORM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY MACHINE LEARNING PLATFORM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY MACHINE LEARNING PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY REINFORCEMENT LEARNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY REINFORCEMENT LEARNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY REINFORCEMENT LEARNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY SUPERVISED LEARNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY SUPERVISED LEARNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY SUPERVISED LEARNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY UNSUPERVISED LEARNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY UNSUPERVISED LEARNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY UNSUPERVISED LEARNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ON PREMISE PLATFORM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ON PREMISE PLATFORM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ON PREMISE PLATFORM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ON PREMISE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CONVENTIONAL HPC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CONVENTIONAL HPC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CONVENTIONAL HPC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY DEDICATED SERVERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY DEDICATED SERVERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY DEDICATED SERVERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ATHEROSCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ATHEROSCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ATHEROSCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY HEART FAILURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY VIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY VIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY OBESITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY OBESITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY OBESITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY NEUROLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY NEUROLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY NEUROLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY NEUROLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ALZHEIMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ALZHEIMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ALZHEIMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PARKINSONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PARKINSONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PARKINSONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PEPTIDE CLASS, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CYCLIC PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CYCLIC PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CYCLIC PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CYCLIC PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY HEAD TO TAIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY HEAD TO TAIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY HEAD TO TAIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY SIDE CHAIN TO SIDE CHAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY SIDE CHAIN TO SIDE CHAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY SIDE CHAIN TO SIDE CHAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY LINEAR PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY LINEAR PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY LINEAR PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY LINEAR PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY LONG PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY LONG PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY LONG PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY SHORT PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY SHORT PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY SHORT PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PEPTIDOMIMETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PEPTIDOMIMETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PEPTIDOMIMETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PEPTIDOMIMETICS, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY BETA PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY BETA PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY BETA PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PEPTOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PEPTOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PEPTOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PRIVATE RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PRIVATE RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PRIVATE RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PUBLIC RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PUBLIC RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PUBLIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY LARGE CRO ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY LARGE CRO ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY LARGE CRO ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY SMALL CRO ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY SMALL CRO ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY SMALL CRO ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CLOUD BASED PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY DEEP LEARNING PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY MACHINE LEARNING PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ON PREMISE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY NEUROLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 177. AMERICAS AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. AMERICAS AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PEPTIDE CLASS, 2018-2032 (USD MILLION)
  • TABLE 179. AMERICAS AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CYCLIC PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 180. AMERICAS AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY LINEAR PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 181. AMERICAS AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PEPTIDOMIMETICS, 2018-2032 (USD MILLION)
  • TABLE 182. AMERICAS AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. AMERICAS AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 184. AMERICAS AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 185. AMERICAS AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CLOUD BASED PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY DEEP LEARNING PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY MACHINE LEARNING PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ON PREMISE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY NEUROLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 198. NORTH AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PEPTIDE CLASS, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CYCLIC PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 200. NORTH AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY LINEAR PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PEPTIDOMIMETICS, 2018-2032 (USD MILLION)
  • TABLE 202. NORTH AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 204. NORTH AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CLOUD BASED PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY DEEP LEARNING PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY MACHINE LEARNING PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ON PREMISE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY NEUROLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PEPTIDE CLASS, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CYCLIC PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 220. LATIN AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY LINEAR PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PEPTIDOMIMETICS, 2018-2032 (USD MILLION)
  • TABLE 222. LATIN AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 224. LATIN AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CLOUD BASED PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY DEEP LEARNING PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY MACHINE LEARNING PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ON PREMISE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY NEUROLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PEPTIDE CLASS, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CYCLIC PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY LINEAR PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PEPTIDOMIMETICS, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CLOUD BASED PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY DEEP LEARNING PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY MACHINE LEARNING PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY ON PREMISE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE AI-DRIVEN PEPTIDE DRUG DISCOVERY PLATFORM MARKET SIZE, BY INFECTI